EquiLend Data & Analytics identifies NetClass Technology as a prime short squeeze candidate, with its short squeeze score at 90.

EquiLend Data & Analytics identifies Regencell Bioscience as a prime short squeeze candidate, with its short squeeze score at 88.

EquiLend Data & Analytics identifies Janover Inc as a prime short squeeze candidate, as the EquiLend Short Squeeze Score surged to 86 indicating extreme potential for continued short covering.

EquiLend Data & Analytics identifies Summit Therapeutics as a prime short squeeze candidate, with its squeeze score surging 43.0 points to 66 in just one month. With utilization approaching 78.98% and elevated borrow fees, short sellers are facing mounting pressure as positive clinical trial results drive momentum.